diethylene glycol ethyl ether oleate | 58401-56-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: diethylene glycol ethyl ether oleate
• 英文别名: 2-(2-ethoxyethoxy)ethyl oleate；ethoxydiglycol oleate；2-(2-ethoxyethoxy)ethyl (Z)-octadec-9-enoate
• CAS: 58401-56-2
• 化学式: C₂₄H₄₆O₄
• 分子量: 398.627
• InChiKey: DIYFELVJCUGJRU-QXMHVHEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  28
• 可旋转键数：
  23
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Method of wound healing using A2B adenosine receptor antagonists
  申请人：Zeng Dewan

  公开号：US20060058322A1

  公开（公告）日：2006-03-16

  The present invention relates to methods of wound healing using A 2B adenosine receptor antagonists. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

  本发明涉及使用A2B腺苷受体拮抗剂进行伤口愈合的方法。该发明还涉及制备此类化合物的方法，以及包含它们的药物组合物。
• [EN] TRIAZINE DERIVATIVES AS UV ABSORBERS<br/>[FR] DERIVES DE LA TRIAZINE UTILISES COMME ABSORBANTS U.V.
  申请人：CIBA SC HOLDING AG

  公开号：WO2004064797A1

  公开（公告）日：2004-08-05

  The present invention relates to new compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, and R8 independently from each other are hydrogen; C1-C18alkyl; C2-C18alkenyl; C5-C7,cycloalkyl; C1-C6alkylene-C5- C7,cycloalkyl; R9 is hydrogen; C1-C18alkyl; C2-C18alkenyl; C5-C7cycloalkyl; C1-C6alkylene-C5-C7cycloalkyl; C6-C10aryl; A is-S-; -O- or -NR10-, wherein R10 has the same meanings as R9; X is COOR11; CONR12R13; SO3,R14; or SO2NR15R16, wherein R11, R12,R13, R14,R15, and R16, have independently from each other the same meanings as R9; to their preparation and to their use as UV absorbers in cosmetic and pharmaceutical formulations.

  本发明涉及公式（I）的新化合物，其中R1、R2、R3、R4、R5、R6、R7和R8彼此独立地是氢；C1-C18烷基；C2-C18烯基；C5-C7环烷基；C1-C6烷基-C5-C7环烷基；R9是氢；C1-C18烷基；C2-C18烯基；C5-C7环烷基；C1-C6烷基-C5-C7环烷基；C6-C10芳基；A是-S-；-O-或-NR10-，其中R10具有与R9相同的含义；X是COOR11；CONR12R13；SO3R14；或SO2NR15R16，其中R11、R12、R13、R14、R15和R16彼此独立地具有与R9相同的含义；以及它们的制备和它们作为化妆品和药用配方中的紫外线吸收剂的用途。
• [EN] SIRT1 ACTIVATING COMPOUNDS<br/>[FR] COMPOSÉS D'ACTIVATION DE SIRT1
  申请人：HARVARD COLLEGE

  公开号：WO2020081654A1

  公开（公告）日：2020-04-23

  Provided herein are methods and compositions for preventing or treating aging, or an aging-related disorder, a disorder associated with inflammation, or for modulating an immune response in a subject in need thereof. In some embodiments, the methods comprise administering to the subject an effective amount of a compound of Formulas I-XIII.

  本文提供了用于预防或治疗衰老、衰老相关疾病、与炎症相关的疾病或调节需要者免疫反应的方法和组合物。在某些实施例中，这些方法包括向受试者施用化合物I-XIII的有效量。
• [EN] COMPOUNDS AND METHODS FOR INHIBITION OF BAX-MEDIATED CELL DEATH<br/>[FR] COMPOSÉS ET PROCÉDÉS PERMETTANT L'INHIBITION DE LA MORT CELLULAIRE MÉDIÉE PAR BAX
  申请人：ALBERT EINSTEIN COLLEGE OF MEDICINE

  公开号：WO2022051384A1

  公开（公告）日：2022-03-10

  This disclosure provides novel compounds and methods for inhibiting BAX activity and BAX-mediated apoptosis, as well as compounds and methods for treating or preventing BAX- mediated disorders.

  本公开提供了用于抑制BAX活性和BAX介导的凋亡的新化合物和方法，以及用于治疗或预防BAX介导的疾病的化合物和方法。
• [EN] BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES CONTENANT DE L'AZOTE POUR UNE UTILISATION EN TANT QU'INHIBITEURS DE LA STÉAROYL-COA DÉSATURASE
  申请人：CV THERAPEUTICS INC

  公开号：WO2009126123A1

  公开（公告）日：2009-10-15

  The present invention discloses bicyclic nitrogen-containing heterocyclic compounds for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, oily skin conditions, metabolic syndrome, and the like.

  本发明揭示了用作硬脂酰辅酶A去饱和酶抑制剂的双环氮杂环化合物。这些化合物在治疗和/或预防由硬脂酰辅酶A去饱和酶（SCD）酶介导的各种人类疾病方面非常有用，特别是与异常脂质水平、心血管疾病、糖尿病、肥胖、油性皮肤状况、代谢综合征等相关的疾病。